Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow ...
Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...
Novo Nordisk (NVO) stock and Eli Lilly (LLY) stock higher as Novo (NVO) reports strong Q4 2024 earnings, driven by sales ...
1hon MSN
Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.
Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...
LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback